107 related articles for article (PubMed ID: 14999238)
21. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
22. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
23. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
Otto T; Rembrink K; Goepel M; Krege S; Meyer-Schwiekerath M; RĂ¼bben H
Urologe A; 1996 Mar; 35(2):142-5. PubMed ID: 8650848
[TBL] [Abstract][Full Text] [Related]
24. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
[TBL] [Abstract][Full Text] [Related]
25. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
26. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
[TBL] [Abstract][Full Text] [Related]
27. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
[TBL] [Abstract][Full Text] [Related]
28. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer.
Robles C; Furst AJ; Sriratana P; Lai S; Chua L; Donnelly E; Solomon J; Sundaram M; Feun L; Savaraj N
Oncol Rep; 2003; 10(4):885-9. PubMed ID: 12792740
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock IF; Osoba D; Stockler MR; Ernst DS; Neville AJ; Moore MJ; Armitage GR; Wilson JJ; Venner PM; Coppin CM; Murphy KC
J Clin Oncol; 1996 Jun; 14(6):1756-64. PubMed ID: 8656243
[TBL] [Abstract][Full Text] [Related]
31. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
Culine S
Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025
[No Abstract] [Full Text] [Related]
32. [Value of mitoxantrone in metastatic hormone-resistant prostate cancer].
Khalaf A; Pfister C; Hellot MF; Dunet F; Moussu J; Grise P
Prog Urol; 2002 Feb; 12(1):37-42. PubMed ID: 11980013
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Osoba D; Tannock IF; Ernst DS; Neville AJ
J Clin Oncol; 1999 Jun; 17(6):1654-63. PubMed ID: 10561201
[TBL] [Abstract][Full Text] [Related]
34. Other chemotherapy regimens including mitoxantrone and suramin.
Siu LL; Moore MJ
Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
[TBL] [Abstract][Full Text] [Related]
35. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
Smith MR; Kaufman D; Oh W; Guerin K; Seiden M; Makatsoris T; Manola J; Kantoff PW
Cancer; 2000 Oct; 89(8):1824-8. PubMed ID: 11042579
[TBL] [Abstract][Full Text] [Related]
36. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Moore MJ; Osoba D; Murphy K; Tannock IF; Armitage A; Findlay B; Coppin C; Neville A; Venner P; Wilson J
J Clin Oncol; 1994 Apr; 12(4):689-94. PubMed ID: 7512127
[TBL] [Abstract][Full Text] [Related]
37. Vindesine-prednisone in the treatment of blast crisis of chronic myeloid leukemia.
Lemoine F; Najman A; Laporte JP; Gorin NC; Duhamel G
Cancer Treat Rep; 1985 Feb; 69(2):203-4. PubMed ID: 3855698
[TBL] [Abstract][Full Text] [Related]
38. Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Joly F; Delva R; Mourey L; Sevin E; Bompas E; Vedrine L; Ravaud A; Eymard JC; Tubiana-Mathieu N; Linassier C; Houede N; Guillot A; Ringensen F; Cojocarasu O; Valenza B; Leconte A; Lheureux S; Clarisse B; Oudard S
BJU Int; 2015 Jan; 115(1):65-73. PubMed ID: 24180479
[TBL] [Abstract][Full Text] [Related]
39. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Osborne CK; Drelichman A; Von Hoff DD; Crawford ED
Cancer Treat Rep; 1983 Dec; 67(12):1133-5. PubMed ID: 6652630
[TBL] [Abstract][Full Text] [Related]
40. Cabazitaxel for castration-resistant prostate cancer.
Shigeta K; Miura Y; Naito Y; Takano T
Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]